Considering the improvement of CV outcome, i.e., the goal of treatment of T2DM, by treatment with SGLT2 inhibitors shown in CVOTs, SGLT2 inhibitors are no longer considered to be oral hypoglycemic agents but rather medication for diabetic complications or for cardiorenal protection. Here, SLC5A2 is linked to type 2 diabetes mellitus.